LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

51.438

77.671

Aktsiakasum

0.4

Dividenditootlus

0.28

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+6.8% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.28%

2.35%

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

305M

12B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

16%

84%

27 / 374 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. dets 2025, 23:58 UTC

Omandamised, ülevõtmised, äriostud

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11. dets 2025, 23:56 UTC

Tulu

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Tulu

Costco Same-Store Sales, Membership Fees Rose in 1Q

11. dets 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

11. dets 2025, 23:44 UTC

Market Talk

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11. dets 2025, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11. dets 2025, 23:31 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:35 UTC

Tulu

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11. dets 2025, 22:30 UTC

Tulu

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11. dets 2025, 22:05 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

11. dets 2025, 21:39 UTC

Tulu

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11. dets 2025, 21:39 UTC

Tulu

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11. dets 2025, 21:38 UTC

Tulu

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11. dets 2025, 21:37 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11. dets 2025, 21:37 UTC

Market Talk

Broadcom Sees AI Revenue Doubling -- Market Talk

11. dets 2025, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Dexus Aiming for Long-Term Holding of A$50M in Fund

11. dets 2025, 21:28 UTC

Market Talk

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus: Third Party Investors to Contribute Remainder

11. dets 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11. dets 2025, 21:25 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

6.8% tõus

12 kuu keskmine prognoos

Keskmine 110.55 USD  6.8%

Kõrge 125 USD

Madal 100 USD

Põhineb 12 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

8

Osta

4

Hoia

0

Müü

Sentiment

By Acuity

27 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat